Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Enhance Nutraceutical
WARNING LETTER
•Enhance Nutraceutical

Enhance Nutraceutical – FDA Warning Letter

Record Details

The FDA issued a Warning Letter to Enhance Nutraceutical after reviewing their websites, including www.enhancenutraceutical.com, www.diaberex.com, and others. The agency determined that the company markets products such as "Diaberex," "Detorex," "Naeleens," "Angirx," "Hard Rod Plus," and "Vigarexx" as unapproved new drugs and misbranded drugs, violating the Federal Food, Drug, and Cosmetic Act (FD&C Act).

These products are considered drugs under section 201(g)(1) due to claims for treating serious conditions like type 2 diabetes, hypertension, heart disease, erectile dysfunction, and enlarged prostate. They are deemed "new drugs" under section 201(p) because they are not generally recognized as safe and effective, and are marketed without FDA-approved applications, violating sections 301(d) and 505(a). Furthermore, these products are misbranded under section 502(f)(1) because they address conditions not amenable to self-diagnosis and treatment, making adequate directions for laypersons impossible (21 CFR § 201.5). Introducing such misbranded drugs into interstate commerce violates section 301(a).

Additionally, FDA laboratories confirmed that other Enhance Nutraceutical products, "ZenMaxx," "Instant Hard Rod," and "RigiRx Plus," contained the undeclared drug ingredient aminotadalafil, an analog of tadalafil (Cialis), which is unlawful. The company must notify the FDA within fifteen working days of specific corrective actions taken, including steps to prevent recurrence, and provide supporting documentation. Failure to comply could lead to further regulatory action.

Company
Enhance Nutraceutical
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Howard Sklamberg (Partner)
View Company Profile

ID · 09239a72-3734-4b39-91b4-9afeeabf0cad

Violation Codes7
21 U.S.C. 321(g)(1)21 U.S.C. 321(p)21 U.S.C. 331(d)21.U.S.C. 355(a)21 U.S.C. 352(f)(1)21 CFR 201.521 U.S.C. 331(a)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Enhance Nutraceutical
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.